“…Previous research on corporate governance mechanisms shows that board interlocking (Davis, 1991), CEO duality (Al Dah et al, 2017;Chen et al, 2021;Jebran et al, 2022), CEO tenure (Arikawa and Mitsusada, 2011), executive compensation plans (Azevedo et al, 2021;Heron and Lie, 2006), institutional ownership (Bhojraj et al, 2017;Davis, 1991;O. Harris and Madura, 2010) and the presence of staggered boards (Heron and Lie, 2015) are corporate governance drivers that positively influence the adoption of poison pills, whereas board size (Azevedo et al, 2021;Loh, 1994) and CEO/managerial ownership (Al Dah et al, 2017;Arikawa and Mitsusada, 2011;Lie, 2006, 2015) influence negatively.…”